Home Neglected Parasitic Diseases Drug Development Consortium News Contact KINDReD SCIENTIFIC ADVISORY BOARD  The consortium’s advisory board is made up of experts who have experience at every point of the preclinical drug pipeline and beyond. Their role is to provide assistance and advice on best practice in drug related research decisions   Professor Réto Brun Head Parasite Chemotherapy Swiss Tropical and Public Health Inst. CH-4002 Basel, Switzerland  Professor Brun is Professor of Medical Parasitology at the Swiss Tropical and Public Health Institute and head of the Parasite Chemotherapy Group. At the STI he is involved with the in vitro cultivation of African trypanosomes and other protozoans of medical or veterinary importance, the control and epidemiology of drug resistance of African trypanosomes and the discovery and preclinical development of new drugs against parasitic protozoa (in particular malaria and human African trypanosomiasis).    He obtained his PhD in Medical Parasitology, from the University of Basel, Switzerland.  His past professional activities include postdoctoral studies at the University of California Irvine. Professor Brun was a member of the board of directors of DNDi until 2011.    Jose M. Coterón, PhD Kinetoplastid DPU-DDW GlaxoSmithKline Tres Cantos, Spain  The Tres Cantos Medicines Development Campus (MDC) is a GlaxoSmithkline Discovery Performance Unit fully dedicated to the discovery and development of new medicines for the treatment of diseases of the developing world (GSK DDW) such as malaria, tuberculosis, leishmaniasis and trypanosomiasis.    Eric Chatelain, PhD, Head of Drug Discovery, DNDi Chemin Louis-Dunant 15, 1202 Geneva, Switzerland  Dr Chatelain joined the DNDi in July 2007 as a senior project manager focusing on screening and discovery projects for new drugs for the treatment of human African trypanosomiasis (HAT), leishmaniasis and Chagas disease.   Prior to joining DNDi, Dr. Chatelain held various positions at Spirig Pharma Ltd., a Swiss-based company developing dermatology drugs. Most recently, he served as the Spirig Pharma’s Head of Preclinical Research.   Dr. Chatelain completed postdoctoral fellowships at the Imperial Cancer Research Fund, in London, UK and the Friedrich Miescher Institute in Basel, Switzerland.   He earned his PhD in Biochemistry at the National Institute of Applied Sciences, Lyon France.  About the DNDi The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit research and development (R&D) organization working to deliver new treatments for the most neglected diseases, in particular sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, filaria, and paediatric HIV/AIDS. Since its inception in 2003, DNDi has delivered six new treatments: two fixed-dose antimalarials (ASAQ and ASMQ); nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness; sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa; a set of combination therapies for visceral leishmaniasis in Asia; and a paediatric dosage form of benznidazole for Chagas disease. DNDi was founded by Médecins Sans Frontières/Doctors without Borders (MSF), Indian Council of Medical Research, Kenya Medical Research Institute, Brazil’s Oswaldo Cruz Foundation, Ministry of Health of Malaysia, and Institut Pasteur in France, with the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) as a permanent observer.   www.dndi.org  www.connect2fightneglect.org
© IP Research Consulting 2014

Scientific Advisory Board

DNDi website DNDi website Connect2fightneglect Connect2fightneglect